Patent intelligence · US
US 11654166
Therapeutic bacteriophage compositions for treating Staphylococcus infection
Therapeutic bacteriophage compositions for treating Staphylococcus infection
Patent details — US 11654166
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 23, 2023
- Expiration
- May 18, 2043
- Applicant
- Armata Pharmaceuticals, Inc.
- Claims
- 34
- CPC classes
- A61K, A61K2300/00, A61K31/395, A61K31/43
Quick answer
US 11654166 (Therapeutic bacteriophage compositions for treating Staphylococcus infection) is held by Armata Pharmaceuticals, Inc.. Status: granted. Granted May 23, 2023. Expires May 18, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Armata Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 34
- CPC classes
- A61K, A61K2300/00, A61K31/395, A61K31/43, A61K31/47, A61K31/545
More from Armata Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12268720
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
granted -
US 12239677
Therapeutic bacteriophage compositions for treating Staphylococcus infection
granted -
US 11253557
Therapeutic bacteriophage compositions
granted -
US 10517908
Therapeutic bacteriophage compositions
granted
Frequently asked questions
What is US patent 11654166?
US 11654166 (Therapeutic bacteriophage compositions for treating Staphylococcus infection) is held by Armata Pharmaceuticals, Inc.. Status: granted. Granted May 23, 2023. Expires May 18, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11654166?
Armata Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 11654166 expire?
Our index shows an expiration date of May 18, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.